Non-Hodgkin's Lymphoma Clinical Trial
Official title:
Sequential Myeloablative Stem Cell Transplantation and Reduced Intensity Allogeneic Stem Cell Transplantation in Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma and Hodgkin's Disease
Verified date | March 2019 |
Source | Columbia University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The sequential combination of myeloablative therapy and autologous stem cell transplantation (APBSCT) followed by a reduced intensity allogeneic stem cell transplant (Allo SCT) and post SCT adoptive cellular immunotherapy will be well tolerated in patients with refractory or recurrent non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD).
Status | Completed |
Enrollment | 30 |
Est. completion date | October 22, 2014 |
Est. primary completion date | October 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 55 Years |
Eligibility |
Inclusion Criteria: Patient must have adequate organ function as below - Adequate renal function defined as: 1. Serum creatinine less than or equal to 2.0 x normal, or 2. Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 40 ml/min/m2 or >60 ml/min/1.73 m2 or an equivalent GFR as determined by the institutional normal range - Adequate liver function defined as: 1. Total bilirubin <2.0 x normal; or 2. Serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase (AST)) or serum glutamic-pyruvic transaminase (SPGT) (alanine aminotransferase (ALT)) <5.0 x normal - Adequate cardiac function defined as: 1. Shortening fraction of >27% by echocardiogram, or 2. Ejection fraction of >47% by radionuclide angiogram or echocardiogram - Adequate pulmonary function defined as: 1. Diffusing capacity of the lungs for carbon monoxide (DLCO) >50% by pulmonary function test for autologous transplant 2. DLCO > 40% by pulmonary function test for reduced intensity allogeneic transplant 3. For children who are uncooperative, no evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry >94% in room air. Disease Status (Eligibility) - Patients with Non-Hodgkin's Lymphoma with either of the following: 1. Primary induction failure (failure to achieve initial CR) who have a partial response (PR) or stable disease (SD) with reinduction chemotherapy. *All patients are required to have a biopsy regardless of positron emission tomography (PET)/Gallium results. 2. Patients with 1st PR, 2nd CR, 2nd PR, or 2nd SD following reinduction chemotherapy 3. Patients with 3rd CR, 3rd PR, 3rd SD following reinduction chemotherapy - Patients with Hodgkin's Disease with either of the following: 1. Primary induction failure (failure to achieve initial CR) and/or primary refractory disease. 2. First relapse 1. Early relapse (within 12 months off therapy) (excluding those who received no therapy or radiation therapy only for initial therapy) 2. Late relapse (greater than 12 months off therapy). Only patients with recurrent Stage III or IV disease and/or those with B symptoms at relapse (all other late relapses are excluded). 3. Second relapse. 4. Third relapse. - Patients must achieve a CR, PR or SD after reinduction chemotherapy. Exclusion Criteria: - Patients with NHL or HD with 4th or greater CR, PR, and/or SD - Patients with progressive disease (PD) unresponsive to reinduction chemo, radio, or immunotherapy - Hodgkin's Disease in late relapse (other than those discussed above). - Patients with post-transplant lymphoproliferative disease following a solid organ transplantation or AIDS associated NHL - Patients who don't have an eligible donor - Women who are pregnant |
Country | Name | City | State |
---|---|---|---|
United States | Children's Memorial Hospital in Chicago | Chicago | Illinois |
United States | Duke University | Durham | North Carolina |
United States | Hackensack University Medical Center | Hackensack | New Jersey |
United States | Medical College of Wisconsin | Milwaukee | Wisconsin |
United States | Columbia University Medical Center | New York | New York |
United States | New York Medical College | Valhalla | New York |
Lead Sponsor | Collaborator |
---|---|
Columbia University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Total Number of Subjects With a Complete Response (CR) Following Myeloablative Conditioning (MAC) and Autologous Stem Cell Transplantation (AutoSCT) | Complete Response is defined as the complete resolution of B symptoms (i.e., weight loss, night sweats and fever) and normalization of all sites of disease on the basis of physical exam, bone marrow biopsy, and imaging studies. | Up to 1 year post-transplantation | |
Primary | Total Number of Subjects With a Disease Relapse or Progression Following MAC AutoSCT | Includes subjects with any measurable growth of disease in a previously affected site or detection of disease in a new site confirmed by biopsy. | Up to 1 year post-transplantation | |
Primary | Total Number of Subjects With Partial Response or Stable Disease Following MAC AutoSCT | Total includes subjects with partial response and patients with stable disease, defined as <50% reduction in measurable disease or the uninterrupted persistence of B symptoms. | Up to 1 year post-transplantation | |
Secondary | Time to Neutrophil Engraftment | Following MAC AutoSCT, the median time to neutrophil (PMN) recovery will be measured. | Up to 1 year post-transplantation | |
Secondary | Time to Platelet Engraftment | Following MAC AutoSCT, the median time to platelet recovery will be measured. | Up to 1 year post-transplantation | |
Secondary | Total Number of Subjects With Grade II-IV Acute Graft-versus-Host-Disease (GVHD) | The criteria for grading is based on extent of organ involvement (i.e., Skin, Liver and Gut - rash on >50% of skin, bilirubin 2-3 mg/dl, diarrhea > 500 ml/day) with Grade II being better outcome and Grade IV being worse outcome. | Up to 1 year post-transplantation | |
Secondary | Total Number of Subjects That Experienced Transplant-related Mortality (TRM) | Status as subjects died post-AlloHCT | Up to 1 year post-transplantation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT01878890 -
Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.
|
Phase 1 | |
Completed |
NCT04152148 -
A Phase I Clinical Trial of BAT4306F on Safety, Tolerability and Pharmacokinetics for Patients
|
Phase 1 | |
Recruiting |
NCT05096234 -
18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma
|
Phase 2 | |
Recruiting |
NCT05191225 -
Ultrafast Truxima Infusion in Non-Hodgkin's Lymphoma: Txagorapid Study
|
Phase 4 | |
Recruiting |
NCT05623982 -
Phase Ib/II Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03664635 -
MB-CART20.1 Lymphoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT02356159 -
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
|
Phase 1/Phase 2 | |
Terminated |
NCT01699581 -
Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant
|
Phase 2 | |
Completed |
NCT01763398 -
Analysis of the Risk Factors for the Neutropenic Fever in the High Risk NHL Patients for Developing Febrile Neutropenia Who Received 3-weekly CHOP-like Chemotherapy With Primary G-CSF Prophylaxis; Prospective Multicenter Observation Study
|
N/A | |
Completed |
NCT01205503 -
Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release
|
Phase 2 | |
Completed |
NCT00975975 -
Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer
|
Phase 2 | |
Completed |
NCT00969462 -
Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma
|
Phase 4 | |
Completed |
NCT00659425 -
CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
|
Phase 1 | |
Completed |
NCT00608907 -
An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)
|
Phase 1 | |
Terminated |
NCT00475332 -
Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar
|
Phase 2 | |
Withdrawn |
NCT00577161 -
Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL
|
Phase 3 | |
Completed |
NCT00533728 -
Safety of Soluble Beta-Glucan (SBG) in Treatment of Patients With Non-Hodgkin's Lymphoma
|
Phase 1 | |
Completed |
NCT00430352 -
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
|
Phase 4 | |
Completed |
NCT00581646 -
Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance
|
N/A |